Physician profile
David D Liu
NPI 1225050404
$6,696.39
in general payments reported to CMS, 2019-2025
41 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $513 · 2021: $1,489 · 2022: $1,311 · 2023: $1,253 · 2024: $833 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $982.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $610.55 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $555.01 | 2022-2024 | Caplyta |
| Glaxosmithkline, LLC. | $551.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $512.46 | 2019-2025 | Epclusa |
| Lilly USA, LLC | $503.93 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $433.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.76 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $246.84 | 2019-2023 | |
| Grifols USA, LLC | $223.58 | 2020-2023 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $178.52 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amgen INC. | $150.28 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $139.86 | 2021 | |
| Boston Scientific Corporation | $121.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.47 | 2019-2025 | Jardiance, Synjardy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $97.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $85.69 | 2019-2021 | |
| Novo Nordisk INC | $85.55 | 2019-2021 | |
| Shield Therapeutics INC | $73.33 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $60.83 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $54.29 | 2023 | Austedo Xr, Austedo |
| Medtronic, INC. | $53.47 | 2022-2023 | Minimed 780g |
| Abbott Laboratories | $51.23 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $48.94 | 2025 | Korlym |
| Electromed, INC. | $47.28 | 2023-2024 | Smartvest |
| Ucb, INC. | $46.74 | 2023 | Nayzilam |
| Daiichi Sankyo INC. | $46.29 | 2024 | Injectafer |
| Ibsa Pharma INC. | $39.97 | 2021 | |
| Baxter Healthcare | $35.07 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Seqirus USA INC | $31.61 | 2025 | Flucelvax, Fluad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.32 | 2025 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $28.68 | 2021 | |
| Amarin Pharma, INC. | $28.07 | 2021 | |
| Ardelyx, INC. | $22.61 | 2024 | Ibsrela |
| Recordati_rare_diseases_inc. | $21.83 | 2024 | Signifor Lar, Isturisa |
| Biogen, INC. | $17.01 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.34 | 2021 | |
| Exact Sciences Corporation | $15.18 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $14.40 | 2019 | |
| Acadia Pharmaceuticals INC | $12.10 | 2019 | |
| Allergan, INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.